{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:59:54Z","timestamp":1790488794245,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ijantimicag.2017.06.017","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T19:46:03Z","timestamp":1499715963000},"page":"326-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Current antifungal treatment of fusariosis"],"prefix":"10.1016","volume":"51","author":[{"given":"Abdullah M.S.","family":"Al-Hatmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandro","family":"Bonifaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Ranque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sybren de Hoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques F.","family":"Meis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ajcp\/29.3.257","article-title":"Keratomycosis caused by Fusarium oxysporum","volume":"29","author":"Mikami","year":"1958","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0015","doi-asserted-by":"crossref","first-page":"e1005464","DOI":"10.1371\/journal.ppat.1005464","article-title":"Fusarium: molecular diversity and intrinsic drug resistance","volume":"12","author":"Al-Hatmi","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.fgb.2012.12.004","article-title":"Phylogenetic analyses of RPB1 and RPB2 support a middle Cretaceous origin for a clade comprising all agriculturally and medically important fusaria","volume":"52","author":"O'Donnell","year":"2013","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0025","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1128\/JCM.02016-14","article-title":"Name changes in medically important fungi and their implications for clinical practice","volume":"53","author":"de Hoog","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3114\/sim.2007.59.01","article-title":"The current status of species recognition and identification in Aspergillus","volume":"59","author":"Geiser","year":"2007","journal-title":"Stud Mycol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0035","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00014-07","article-title":"Fusarium infections in immunocompromised patients","volume":"20","author":"Nucci","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0040","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.46.7.2273-2275.2002","article-title":"Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis","volume":"46","author":"Ortoneda","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/myc.12273","article-title":"Spectrum of Fusarium infections in tropical dermatology evidenced by multilocus sequencing typing diagnostics","volume":"58","author":"van Diepeningen","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/2040620711410098","article-title":"Invasive fungal infections in acute leukemia","volume":"2","author":"Bhatt","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0055","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1038\/emi.2016.126","article-title":"Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging human opportunist from 1958 to 2015","volume":"5","author":"Al-Hatmi","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.02456-15","article-title":"International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method","volume":"60","author":"Espinel-Ingroff","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0065","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1128\/JCM.02371-07","article-title":"Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex","volume":"46","author":"O'Donnell","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0070","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10096-015-2405-y","article-title":"Emergence of fusarioses in a university hospital in Turkey during a 20-year period","volume":"34","author":"Dalyan Cilo","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0075","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/JCM.00308-13","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0080","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2010.01.010","article-title":"Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998\u20132009","volume":"60","author":"Campo","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0090","doi-asserted-by":"crossref","first-page":"20150460","DOI":"10.1098\/rstb.2015.0460","article-title":"Clinical implications of globally emerging azole resistance in Aspergillus fumigatus","volume":"371","author":"Meis","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2334-14-219","article-title":"Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis","volume":"14","author":"Rodrigues","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.1128242","article-title":"Aneuploidy and isochromosome formation in drug-resistant Candida albicans","volume":"313","author":"Selmecki","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0105","doi-asserted-by":"crossref","first-page":"e1000848","DOI":"10.1371\/journal.ppat.1000848","article-title":"Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes","volume":"6","author":"Sionov","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0110","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S1473-3099(16)30138-4","article-title":"In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management","volume":"16","author":"Verweij","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jac\/39.2.163","article-title":"In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains","volume":"39","author":"Pujol","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0120","first-page":"1068","article-title":"Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex","volume":"70","author":"Al-Hatmi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4161\/viru.2.2.15015","article-title":"The challenge of managing fusariosis","volume":"2","author":"Muhammed","year":"2011","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0130","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/ijd.12906","article-title":"Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases","volume":"54","author":"Ranawaka","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0135","first-page":"70","article-title":"Onychomycosis by molds. Report of 78 cases","volume":"17","author":"Bonifaz","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000357764","article-title":"Oral terbinafine and itraconazole treatments against dermatophytes appear not to favor the establishment of Fusarium spp. in nail","volume":"228","author":"Verrier","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jinf.2013.08.011","article-title":"Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis","volume":"68","author":"Varon","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0150","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s10096-015-2410-1","article-title":"Fusarium spp. is able to grow and invade healthy human nails as a single source of nutrients","volume":"34","author":"Galletti","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bjd.13589","article-title":"Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole","volume":"173","author":"Al-Hatmi","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/myc.12315","article-title":"In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs","volume":"58","author":"Badali","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0165","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2230.2009.03698.x","article-title":"In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis","volume":"35","author":"Bueno","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/jdv.12151","article-title":"Identification and antifungal susceptibility of fungi isolated from dermatomycoses","volume":"28","author":"Silva","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0175","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.diagmicrobio.2016.05.006","article-title":"In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method","volume":"85","author":"Taj-Aldeen","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000335093","article-title":"Efficacious treatment of non-dermatophyte mould onychomycosis with topical amphotericin B","volume":"223","author":"Lurati","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11046-016-0042-3","article-title":"Fungal keratitis in North India: spectrum of agents, risk factors and treatment","volume":"181","author":"Ghosh","year":"2016","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0190","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12879-014-0588-y","article-title":"Keratitis by Fusarium temperatum, a novel opportunist","volume":"14","author":"Al-Hatmi","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0195","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s11046-016-0060-1","article-title":"Fusarium dimerum species complex (Fusarium penzigii) keratitis after corneal trauma","volume":"181","author":"do Carmo","year":"2016","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/myc.12578","article-title":"Multidrug-resistant Fusarium in keratitis: a clinico-mycological study of keratitis infections in Chennai, India","volume":"60","author":"Tupaki-Sreepurna","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0205","doi-asserted-by":"crossref","first-page":"3436415","DOI":"10.1155\/2016\/3436415","article-title":"A combination of intrastromal and intracameral injections of amphotericin B in the treatment of severe fungal keratitis","volume":"2016","author":"Hu","year":"2016","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/09273948.2015.1057597","article-title":"Evaluation of amphotericin B in the management of fungal keratitis: randomized controlled trial","volume":"24","author":"Sharma","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0215","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/08982104.2016.1224899","article-title":"Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy","volume":"27","author":"Fu","year":"2017","journal-title":"J Liposome Res"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0220","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajo.2013.10.004","article-title":"In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial","volume":"157","author":"Lalitha","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0225","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bjophthalmol-2014-306485","article-title":"Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial","volume":"99","author":"Sharma","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0230","first-page":"1098","article-title":"Efficacy of anti-fungal agents in the cornea. I. A comparative study","volume":"24","author":"O\u2032Day","year":"1983","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0235","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archopht.125.6.789","article-title":"Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis","volume":"125","author":"Lalitha","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0240","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archophthalmol.2010.102","article-title":"Comparison of natamycin and voriconazole for the treatment of fungal keratitis","volume":"128","author":"Prajna","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0245","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jamaophthalmol.2016.4096","article-title":"Effect of oral voriconazole on fungal keratitis in the mycotic ulcer treatment trial II (MUTT II): a randomized clinical trial","volume":"134","author":"Prajna","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0250","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dkv421","article-title":"In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis","volume":"71","author":"Al-Hatmi","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0255","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","article-title":"The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0260","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ophtha.2014.03.004","article-title":"Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis","volume":"121","author":"Sun","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0265","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0275","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bjo.86.7.829-a","article-title":"Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis","volume":"86","author":"Sponsel","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0280","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2006.10.048","article-title":"Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592)","volume":"143","author":"Tu","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0285","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CMR.16.4.730-797.2003","article-title":"Current perspectives on ophthalmic mycoses","volume":"16","author":"Thomas","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0290","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0295","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/cid\/ciu947","article-title":"Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients","volume":"60","author":"Garnica","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0300","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cmi.2014.09.004","article-title":"An outbreak of invasive fusariosis in a children's cancer hospital","volume":"21","author":"Litvinov","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0305","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/AAC.00636-16","article-title":"Antimold prophylaxis may reduce the risk of invasive fusariosis in hematologic patients with superficial skin lesions with positive culture for Fusarium","volume":"60","author":"Varon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087784","article-title":"Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing","volume":"9","author":"Nucci","year":"2014","journal-title":"PLoS ONE"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2017.06.017_bib0315","doi-asserted-by":"crossref","first-page":"ii31","DOI":"10.1093\/jac\/dkw394","article-title":"The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis)","volume":"71","author":"Lortholary","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0320","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictor of 84 patients with hematologic malignancies and Fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0325","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/383319","article-title":"Fusarium infection in hematopoietic stem cell transplant recipients","volume":"38","author":"Nucci","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0330","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0335","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkn215","article-title":"Combined therapy in treatment of murine infection by Fusarium solani","volume":"62","author":"Ru\u00edz-Cendoya","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0340","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1128\/AAC.01606-08","article-title":"Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum","volume":"53","author":"Ru\u00edz-Cendoya","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0345","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.43.5.1256","article-title":"In vitro and in vivo experimental activities of antifungal agents against Fusarium solani","volume":"43","author":"Guarro","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0350","doi-asserted-by":"crossref","first-page":"ofv099","DOI":"10.1093\/ofid\/ofv099","article-title":"Invasive fusariosis in the voriconazole era: single-center 13-year experience","volume":"2","author":"Stempel","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0355","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0360","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2014-04-516211","article-title":"How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach","volume":"124","author":"Nucci","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0365","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/2049936113491936","article-title":"Invasive fungal infections in transplant recipients","volume":"1","author":"Vazquez","year":"2013","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0375","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0380","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.01445-09","article-title":"Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani","volume":"54","author":"Wiederhold","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0385","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1111\/j.1439-0507.2011.02032.x","article-title":"Emerging moulds: epidemiological trends and antifungal resistance","volume":"54","author":"Miceli","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0390","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/myc.12212","article-title":"Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(\u00ae) registry","volume":"57","author":"Horn","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0395","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00277-013-1943-6","article-title":"Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis","volume":"93","author":"Wu","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0400","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.healun.2003.09.033","article-title":"Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient","volume":"23","author":"Herbrecht","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0405","series-title":"Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE trials","author":"Cornely","year":"2014"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0410","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1086\/374895","article-title":"Resolution of fungemia due to Fusarium species in a patient with acute leukemia treated with caspofungin","volume":"36","author":"Apostolidis","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0415","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/INF.0000000000001396","article-title":"Disseminated fusariosis in immunocompromised children\u2014analysis of recent cases identified in the global FungiScope registry","volume":"36","author":"Hassler","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0420","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/01.inf.0000143649.90952.41","article-title":"Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole","volume":"23","author":"Guzman-Cottrill","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0425","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/JCM.41.10.4898-4900.2003","article-title":"Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia","volume":"41","author":"Durand-Joly","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0430","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1439-0507.2006.01346.x","article-title":"Treating disseminated fusariosis: amphotericin B, voriconazole or both?","volume":"50","author":"Ho","year":"2007","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0435","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1345\/aph.1D292","article-title":"Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia","volume":"39","author":"Makowsky","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0440","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00277-003-0795-x","article-title":"Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B","volume":"83","author":"Rothe","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0445","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2003.09.003","article-title":"In vitro interactions of licensed and novel antifungal drugs against Fusarium spp","volume":"48","author":"Ortoneda","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0450","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.riam.2013.01.002","article-title":"Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium","volume":"30","author":"Spader","year":"2013","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0455","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijantimicag.2007.09.005","article-title":"In vitro interactions of antifungal agents against clinical isolates of Fusarium spp","volume":"31","author":"C\u00f3rdoba","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0460","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijantimicag.2016.12.015","article-title":"Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation","volume":"49","author":"Martin-Vicente","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2017.06.017_bib0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0470","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2217\/fmb.15.108","article-title":"Rapid identification of clinical members of Fusarium fujikuroi complex using MALDI-TOF MS","volume":"10","author":"Al-Hatmi","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.06.017_bib0475","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jof3020019","article-title":"Antifungal susceptibility testing of Fusarium: a practical approach","volume":"3","author":"Al-Hatmi","year":"2017","journal-title":"J Fungi"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T18:23:20Z","timestamp":1659205400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0924857917302662"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current antifungal treatment of fusariosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}